DISCOVER: More Rapid and Sustained Protective Levels of TFV-DP With FTC/TAF vs FTC/TDF as PrEP

July 21-24, 2019; Mexico City, Mexico

Differences in pharmacokinetics may account for the trend toward lower HIV infection rates with FTC/TAF vs FTC/TDF as PrEP in MSM and transgender women enrolled on the phase III DISCOVER trial.

Format: Microsoft PowerPoint (.ppt)
File Size: 283 KB
Released: July 26, 2019

Acknowledgements

Provided by USF

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
IAS 2019 Media Partner Logo
Educational grant provided by:
Gilead Sciences
ViiV Healthcare

Related Content

Dr Kenric Ware discusses how technology and social media can impact PrEP adherence and persistence, from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: January 23, 2023

Dr Kenric Ware discusses considerations for ongoing PrEP candidacy and persistence, from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: January 20, 2023

Dr Kenric Ware discusses opportunities to increase PrEP awareness and uptake on college campuses in this commentary from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: January 19, 2023

In this case-based video module, Dr Jill Blumenthal shares key data and recommendations about PrEP in transgender young adults, from Clinical Care Options (CCO)

Jill Blumenthal, MD, MAS Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 9, 2023 Expired: January 8, 2024

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings